They found that IFN-β therapy is associated with a greater production of vitamin D from sun exposure, suggesting part of the therapeutic effects of IFN-β on relapse in MS, which may be through the modulation of vitamin D metabolism [75]. Here, IFNB1 is linked to myeloid sarcoma.